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Brief CommunicationDysregulation of a novel miR-23b/27b-p53 axis
impairs muscle stem cell differentiation of
humans with type 2 diabetesTora I. Henriksen 1, Peter K. Davidsen 1,2, Maria Pedersen 1, Heidi S. Schultz 3, Ninna S. Hansen 4,
Therese J. Larsen 1,5, Allan Vaag 4,6, Bente K. Pedersen 1,6, Søren Nielsen 1,8, Camilla Scheele 1,7,*,8ABSTRACT
Objective: MicroRNAs (miRNAs) are increasingly recognized as ﬁne-tuning regulators of metabolism, and are dysregulated in several disease
conditions. With their capacity to rapidly change gene expression, miRNAs are also important regulators of development and cell differentiation. In
the current study, we describe an impaired myogenic capacity of muscle stem cells isolated from humans with type 2 diabetes (T2DM) and
assess whether this phenotype is regulated by miRNAs.
Methods: We measured global miRNA expression during in vitro differentiation of muscle stem cells derived from T2DM patients and healthy
controls.
Results: The mir-23b/27b cluster was downregulated in the cells of the patients, and a pro-myogenic effect of these miRNAs was mediated
through the p53 pathway, which was concordantly dysregulated in the muscle cells derived from humans with T2DM.
Conclusions: Our results indicate that we have identiﬁed a novel pathway for coordination of myogenesis, the miR-23b/27b-p53 axis that, when
dysregulated, potentially contributes to a sustained muscular dysfunction in T2DM.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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MicroRNAs (miRNAs) are short, non-coding regulators of protein
abundance [1]. Acting at the posttranscriptional level miRNAs quickly
alters the biological setting of a cell, making them suitable regulators of
tissue development and differentiation [1]. Several recent studies
report that miRNAs are induced by physical activity [2,3] and mediate
metabolic control by regulating glucose metabolism and insulin
signaling [4e7] as well as pancreatic beta cell survival [8]. In human
skeletal muscle, the global miRNA proﬁle is dysregulated already
during the pre-state of type 2 diabetes [9], while speciﬁc changes
occur following establishment of the disease [9,10]. It was further
reported that non-obese patients with type 2 diabetes (T2DM) had
dysregulated miRNAs which associated to genes involved in devel-
opment and differentiation [9]. We therefore hypothesized that non-
obese T2DM patients would have alterations in their skeletal muscle
at a stem cell level, resulting in impaired miRNA-mediated muscle cell
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and the sarcolemma of the muscle ﬁber [11]. Muscle stem cells
contribute to muscle hypertrophy [12] and, although debated, could
thus have a role in replacing old and damaged muscle cells in a
continuous manner [13].
To our knowledge, myogenic differentiation is poorly investigated in
T2DM in humans, however, a decline in muscle mass and function in
T2DM patients compared with healthy control subjects becomes
clearer in aging patients [14e16]. Previous studies in muscle strength
in T2DM in humans have suggested that loss of muscle quality may be
due to diabetic neuropathy [17] yet the mechanism behind this loss of
muscle quality currently remains unclear. The severe decline in
skeletal muscle function during T2DM in terms of deﬁcient glucose
metabolism and insulin signaling certainly suggests a possibility for
impaired muscle maintenance. We utilized a previously reported model
system of isolated muscle stem cells from several donors which had
T2DM or were healthy. Insulin resistance, inﬂammation and
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abnormalities preserved, from an in vivo state of T2DM, in isolated,
in vitro differentiated muscle stem cells [18e22]. Thus, to address our
hypothesis, we studied miRNA regulation and differentiation of muscle
stem cells derived from humans with T2DM or from healthy controls.
2. EXPERIMENTAL PROCEDURES
Additional information can be found in supplemental experimental
procedures.
2.1. Human subjects
Human tissue and cell cultures were obtained from a subset of donors
included in a previously described study [23]. The clinical character-
istics of the human subjects are listed in Table 1. All participants gave
written informed consent before inclusion and the study was performed
according to the Declaration of Helsinki and approved by The Regional
Committee on Biomedical Research Ethics in Denmark (KF 01-141/04).
2.2. Human muscle stem cells
Muscle stem cells were isolated from vastus lateralis muscle biopsies
and cultured and differentiated as previously described [18].
2.3. Flow cytometry
Isolated muscle stem cells were propagated in growth medium as
described above until 70% conﬂuence. Cells were detached using
TrypLETM Express, and subsequently washed twice in wash buffer
(phosphate buffered saline (PBS) containing 2% FBS and 0.01% NaN3)
and once in staining buffer (PBS containing 2% FBS, 1% human
serum, and 0.01% NaN3). Cells were stained with anti-human CD56-
APC, CD90-PerCP-Cy5.5, CD31-PE, and CD45-BV421 (all from BD
Bioscience) for 20 min and subsequently washed twice in wash buffer.
Data was acquired using a FACSFortessa (BD Biosciences). For
compensation, single stain was used with one drop of negative control
beads and anti-mouse IgG beads (BD Biosciences). The gating strategy
is shown in Figure S1. Data analysis was performed using Kaluza
software version 1.2 (Beckman Coulter).
2.4. RNA isolation and qPCR
Total RNA was extracted from myocytes using TRIzol according to
manufacturer’s instructions. Quantitative real-time PCR (qPCR) was
performed in triplicate using the ViiA 7 Real-Time PCR platform. The
sequences of the target primers are listed in Supplementary experi-
mental procedures. Data analysis was performed using the compar-
ative method (DDCT). All endogenous control genes utilized in the
study showed signiﬁcant difference CT values between healthy andTable 1 e Clinical characteristics of muscle stem cell donors.
Healthy (n ¼ 8) T2DM (n ¼ 8)
Age (years) 58.0 (50e67) 58.9 (51e65)
BMI (kg/m2) 25.4  1.8 26.2  2.8
Fasting glucose (mmol/L) 5.6  0.6 11.3  4.4**
OGTT 2-hour glucose (mmol/L) 5.1  1.8 20.2  3.8****
Fasting insulin (pmol/L) 29.9  16.5 42.3  17.0
OGTT 2-hour insulin (pmol/L) 154.  125.9 152.6  46.1
HOMA-IR 1.2  0.7 3.9  3.1*
VO2 max (L/min) 3.0  0.6 2.3  0.8
VO2 max (mL/kg/min) 35.7  8.4 26.2  8.4*
Data are means  SE. BMI ¼ body mass index; OGTT ¼ oral glucose tolerance test.
Glucose values are mmol/L, insulin values are pmol/L. Differences between groups
was compared using student’s unpaired t-test. *P < 0.05, **P < 0.001,
****P < 0.0001.
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ensure that observed differences in gene expression were not due to
differences in endogenous control gene expression we therefore
included several endogenous control genes.
2.5. miRNA array analysis
A miRCURY LNA microRNA Array (6th gen - hsa, mmu & rno) (Exiqon,
Denmark) was utilized for global miRNA detection between human
muscle stem cells derived from T2DM subjects and healthy controls
during differentiation. Data has been submitted to GEO: GSE86069.
2.6. MiRNA target prediction analysis
Prediction analysis of KEGG pathways targeted by the identiﬁed miR-
NAs was performed using the DIANA miRPath online software [24]
employing the microT-CDS algorithm.
2.7. miRNA inhibitor/mimic transfection in human myoblasts
Transient transfections of human myoblasts were performed using
pools of either miRNA inhibitor oligonucleotides targeting miR-23b or
miR-27b, or oligonucleotides mimicking endogenous miR-23b and
miR-27b (Exiqon, Denmark). Transfections were performed by incu-
bating myoblasts at day 0 or day 5 of differentiation with 50 nM miRNA
inhibitor and RNAimax Lipofectamine (Invitrogen) for 48 h. Control
conditions were incubated with either a scrambled oligonucleotide
sequence predesigned to not target any miRNA or Lipofectamine with
no oligonucleotide added.
2.8. Immunoﬂourescence microscopy
In vitro differentiated human muscle stem cells were ﬁxated with 4%
Formaldehyde (Sigma) and then permeabilized with 0.5% Triton X-
100. Cells were then incubated with mouse monoclonal anti-
sarcomeric Alpha Actinin antibody (Abcam ab9465) or incubated
with an anti-myosin antibody (DSHB; MF 20 was deposited to the
DSHB by Fischman, D.A. (DSHB Hybridoma Product MF 20)), and
counterstained with 40, 6-diamidino-2-phenylindole (DAPI). Alexa Flour
488 goat anti-mouse antibody was used as the secondary antibody
(Molecular probes). Nuclear counterstaining was performed with
Nucblue Fixed Cell stain ReadyProbes (Molecular probes). Fluores-
cence microscopy was performed with an EVOS FL (Thermo Fisher).
2.9. Statistical analyses
The quantiﬁed miRNA array signals were background corrected and
then normalized using the global LOWESS (LOcally WEighted Scat-
terplot Smoothing) regression algorithm. A two-tailed t-test assuming
unequal variance identiﬁed microRNAs with a p-value below the
Bonferroni cut-off. For visualizing differentially expressed miRNAs
during differentiation a Heatmap was performed using the online tool
CIM miner. For visualizing the effect of T2DM, the online tool Plotly was
used. Statistical analyses were performed using GraphPad Prism 6.0
(GraphPad Software Inc., La Jolla, CA, USA). All data within ﬁgures are
presented as means  SEM. Data in tables are presented as
means  SD. For comparisons between two groups, a Student’s t-test
was used. For multiple comparisons, statistical analysis was per-
formed using two-way ANOVA with Sidak post hoc testing.
3. RESULTS AND DISCUSSION
3.1. Reduced myogenic capacity in cells derived from humans with
T2DM
We compared the myogenic capacity of muscle stem cells obtained
from eight non-obese humans with T2DM that were age- and BMI-en access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 771
Brief Communicationmatched with eight healthy, normal glucose tolerant control subjects. A
schematic ﬁgure of the experimental setup is shown in Figure 1A.
Phase contrast pictures of the cells during the different developmental
stages were recorded (Figure S2).
Using immunoﬂuorescence analysis we observed a severely impaired
differentiation of the muscle stem cells derived from T2DM donors, as
demonstrated by staining for either Myosin-2 or a-actinin (Figure 1B).
Myogenesis is regulated by several transcription factors including
Paired Box 7 (PAX7), Myoblast determination protein 1 (MYOD) and
myogenin (MYOG) [25] as well as muscle-speciﬁc miRNAs, (myomiRs),
including miR-1-3p (miR-1), miR-133a-3p (miR-133a), miR-133b and
mir-206 [26e28]. To further compare the differentiation capacity
between the two groups, we assessed the expression of the above
mentioned myogenic regulators, as well as the structural muscle
marker, Myosin-2. We observed a reduced expression of all myogenic
markers measured in T2DM muscle cells (Figure 1D) as well as of two
of the myomiRs: miR-1 and miR-206 (Figure 1E). A coordinated
expression of both myogenic transcription factors and myomiRs is
required for myogenesis, and in line with previous ﬁndings that MyoD
regulates myomiR expression [28] we found that a decreased
expression of MyoD in the T2DM cells preceded the observed
decreased expression of miR-1 and miR-206 (Figure 1D, E). We next
assessed whether differences in myogenic markers also were present
in skeletal muscle tissue biopsies, and found that MYOD was lower
expressed in humans with T2DM compared to healthy control subjects
(Figure 1C). This ﬁnding supports prior reports [14,15] on loss of
muscle quality in T2DM and demonstrates a previously undescribed
loss of myogenic capacity in these patients. To assure that the loss of
myogenic gene expression observed in the T2DM cells was not due to
a higher degree of inﬁltration by non-muscle cell types in this group,
ﬂow cytometry was applied. CD56, which is speciﬁcally displayed on
human myoblast but not on adipocytes or ﬁbroblasts [29,30], was
expressed on all cell cultures used in the study at either high or in-
termediate levels (Figure 1F,G). All cells were also CD90-positive,
reﬂecting their mesenchymal origin [31], whereas cells were negative
for the hematopoietic marker CD45 and the endothelial marker CD31
(Figure 1F). Thus, both cell groups were CD56þCD90þCD45CD31e,
with no observed difference between groups, suggesting equal purity
of isolations and that any differences in differentiation capacity would
not be related to isolation of different cell types.
In conclusion, we observed a reduced myogenic capacity of muscle
precursor cells derived from humans with T2DM, despite a comparable
myogenic purity of the cell strains between groups, suggesting a
functional decline within the actual muscle stem cells.
3.2. The miRNA signature of differentiating muscle stem cells from
humans with T2DM
We measured the global miRNA expression at three time points during
differentiation in T2DM and healthy muscle stem cells, using a miR-
CURY LNA microRNA Array (6th gen - hsa, mmu & rno) (Exiqon,
Denmark). Consistent with the ﬁndings of a previous study analyzing
in vitro differentiated human muscle cells [32], unsupervised clustering
analysis of the miRNA expression showed a marked upregulation of
myomiRs miR-1, miR-133a, miR-133b and miR-206 in differentiated
compared to undifferentiated myoblasts. Interestingly, miR-1246 and
miR-1290, two miRNAs previously undescribed in skeletal muscle,
were regulated in a distinct temporal expression pattern opposite of the
myomiRs; they were highly expressed in proliferating muscle stem
cells but were downregulated as the cells went through differentiation,
indicating a role of these two miRNAs as novel regulators of muscle
stem cell differentiation (Figure S3A). We thus identiﬁed a time-772 MOLECULAR METABOLISM 6 (2017) 770e779  2017 The Authors. Published by Elsevier GmbH. Thidependent miRNA expression signature in human muscle cells,
whereas no differences between the T2DM and healthy groups were
observed at individual time points (Figure 2A). However, when
combining all three time-points within each group, we found ﬁve
miRNAs that all were downregulated in the T2DM muscle cells
(Figure 2B). These miRNAs included: miR-10a-5p (miR-10a), miR-
23b-3p (miR-23b), miR-27b-3p (miR-27b), miR-193b-3p (miR-193b)
and miR-195-5p (miR-195), ranging from a 0.62- to a 0.84-fold
decrease in the T2DM group which was conﬁrmed by qPCR analysis
(Figure 2C).
However, we did not detect any differences between the groups when
measuring the miRNAs in the corresponding tissues from which the
cells were isolated (Figure S3B), underlining the main weakness with
the study; We utilized an in vitro model and thus cannot exclude that
alterations in miRNA expression occurred as a secondary event, during
in vitro processing. However, muscle tissue is more complex in respect
to cell type composition and physiological context than in vitro
differentiated cells. Other cell types might contribute to expressional
noise that makes it difﬁcult to detect a disease pattern in vivo. With our
cell model, this noise is reduced, making it an attractive approach to
detect small changes in miRNAs which might have great impact on
disease phenotype. Nevertheless, a higher number of study partici-
pants might have been sufﬁcient for detecting a difference even in
tissue biopsies, as a downregulation of miR-10a and miR-27b in
skeletal muscle biopsies of non-obese people with T2DM was previ-
ously described [9]. This supports our ﬁndings and argues for that the
difference observed in miR-27b and miR-23b is a conserved feature
from the in vivo T2DM condition. Furthermore, miR-23b, miR-27b and
miR-195 were also found to be downregulated in a murine model of
cachexia, while miR-27b was actually upregulated in mice with STZ-
induced diabetes [33], supporting a role of miR-23b and miR-27b in
skeletal muscle integrity and, at the same time, emphasizing the
importance of studying these miRNAs in a human model of type 2
diabetes.
3.3. miR-23b and miR-27b are pro-myogenic and target p53
inhibitors
Two of the miRNAs downregulated in the muscle stem cells from
humans with T2DM, miR-23b and miR-27b, caught our particular
interest. As discussed above, miR-27b was downregulated in muscle
tissue of humans with T2DM in a previous study, and miR-23b is
transcribed from the same cluster along with miR-24-1 [34]. In fact,
miR-24-1 was also downregulated in our data set, but with a p-value
of 4.59E-4, this miRNA was just above signiﬁcance after correcting for
multiple testing (data not shown) and was therefore not included in
downstream functional studies. Previous studies have suggested a role
of miR-23b and miR-27b in the regulation of skeletal muscle tissue
quality [35,36]. In addition, miR-27b has been reported to exhibit pro-
myogenic effects in murine cells [37,38] and miR-23a (which has a
high sequence similarity with miR-23b) has been shown to regulate
myosin heavy chain isoforms in murine myoblasts [39]. We thus
decided to examine the role of miR-23b and miR-27b in the differ-
entiation of muscle stem cells derived from non-obese humans with
T2DM and age- and BMI-matched healthy control subjects.
First, we studied differentiation of muscle stem cells derived from
healthy subjects following knockdown of either miR-23b or miR-27b.
Conﬂuent myoblasts were transfected with miRNA inhibitors. Immu-
noﬂuorescence analysis of differentiated myocytes stained for Sarco-
meric alpha actinin (a-actinin) or Myosin-2, demonstrated an impaired
differentiation of the cells depleted for miR-23b or miR-27b
(Figure 3A). In accordance with the imaging analysis, myogenics is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Myogenic transcription factors in differentiating muscle stem cells. (A) Schematic overview of the experimental setup. (B) Muscle stem cells from healthy (n ¼ 8) or
T2DM donors (n ¼ 8) were isolated and differentiated in vitro. Differentiated myocytes were stained for DAPI (blue) and a-actinin (green) or Myosin-2 (green), representative
pictures are shown. (C) qPCR analysis of PAX7, MYOD, MYOG and MYH2 in skeletal muscle biopsies. (D) qPCR analysis of PAX7, MYOD, MYOG and MYH2 in differentiating muscle
cells. (E) qPCR analysis of miR-1, miR-206, miR-133a and miR-133b. F) Flow cytometry analysis of healthy and T2D muscle stem cells, stained for CD56 (APC), CD90 (PerCP-
Cy5.5), CD31 (PE) and CD45 (BV421). Data are means  SEM. * indicates P < 0.05; **P < 0.01.
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Figure 2: Global analysis of miRNA expression during muscle stem cell differentiation. Muscle stem cells from healthy (n ¼ 8) or T2DM (n ¼ 8) donors were harvested as
proliferating myoblasts or during myocyte differentiation. A miRNA array comprising 2383 capture probes was performed. In early differentiation, T2DM cells are n ¼ 7, as one
sample got lost in RNA isolation. A) Heatmap showing temporally regulated miRNAs; red indicates high expression, blue indicates low expression. B) Heatmap of miRNAs that were
differentially expressed between healthy and T2DM groups; red indicates high expression, white indicates low expression. C) qPCR analysis of miR-10a, miR-23b, miR-27b, miR-
193b and miR-195. Data are means  SEM.
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Figure 3: miR-23b and miR-27b regulate human myogenesis and target p53 inhibitors. (AeE) Muscle stem cells from healthy donors (n ¼ 6) were transfected with 50 nM miRNA
inhibitors against miR-23b or miR-27b or a scrambled control for 48 h. A) Transfected and differentiated myocytes were ﬁxed and stained for a-actinin (green) or Myosin-2 (green)
and nuclei (Nucblue, blue). For myogenic gene expression analysis, cells were harvested early in differentiation as aligned myoblasts (BeC) or as differentiated myocytes (DeE).
Predicted targets of miR-23b and miR-27b were measured 48 h post transfection during early differentiation (F). Muscle stem cells from healthy (n ¼ 8) or T2DM (n ¼ 8) donors
were harvested as proliferating myoblasts or during indicated time points of differentiation. mRNA expression of MDM2, RCHY1 and CCNG1 were measured by using qPCR and data
was normalized to PPIA. mRNA expression levels are shown as fold changes from healthy proliferating cells (G). Data are means  SEM. * indicates P < 0.05; **P < 0.01.
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Figure 4: miR-23b and miR-27b regulate the p53 signaling pathway in muscle stem cells. Schematic overview of the proposed interactions between the miR-23b/27b cluster, the
p53 pathway and myogenesis (A). P53 protein levels were measured by electrochemiluminescent immunoassay (BeC). Muscle stem cells from T2DM donors were transfected with
50 nM miR-23b or miR-27b mimics, a scrambled, non-targeting oligonucleotide control and for immunoblots also a lipofectamine only control (LF). Cells were harvested 48 h post
transfection. Protein levels of MDM2, RCHY1, Cyclin G1 and beta tubulin were determined using immunoblotting. A representative blot is shown (D). mRNA expression of MDM2,
RCHY1 and CCNG1 (E) and p21 and RB1 and P53 (F) was measured by qPCR and data was normalized to GAPDH mRNA. Myogenic markers including PAX7 (G), MYOD (H), MYOG (I)
and MYH2 (J). Data are means  SEM. * indicates P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Brief Communicationmarkers were downregulated upon the reduction of miR-23b and miR-
27b (Figure 3BeE). Speciﬁcally, knockdown of either miR-23b or miR-
27b caused a reduction in PAX7 expression during early differentiation
(Figure 3B), and MYOG expression was decreased after knockdown of
miR-27b during late differentiation (Figure 3D), suggesting a reduced
myogenic determination of cells with reduced expression of miR-23b
and 27b.
To determine potential targets of miR-23b and miR-27b, we used DIANA
miRPath [24], combining a nucleotide base pairing prediction algorithm776 MOLECULAR METABOLISM 6 (2017) 770e779  2017 The Authors. Published by Elsevier GmbH. Thi(microT-CDS) with the KEGG pathway database. This analysis assigned
p53 signaling as the most likely pathway to be co-targeted by miR-23b
and miR-27b (Table S1). Several genes known to negatively regulate
p53 expression were speciﬁcally predicted to be targets of miR-23b and
miR-27b, including the RING ﬁnger and CHY zinc ﬁnger domain-
containing protein 1 (RCHY1) [40,41], as well as Cyclin G1 (CCNG1)
[42]. We selected these genes for downstream analysis due to their
established role in cell cycle regulation as this would be important in any
differentiation system. In further support of selecting CCNG1, it wass is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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recently demonstrated in cancer cells, that both miR-23b [43] and miR-
27b [44,45] directly target CCNG1 mRNA, providing an anticancer ef-
fect by diminishing the negative control of p53. In this respect, we decided
to also investigate the ubiquitin-protein ligase Mouse double minute 2
(MDM2) as a potential target for miR-23b and miR-27b, even though this
gene was not included in the results from the DIANA miRPath analysis.
MDM2 is a major inhibitor of p53 and p21 and thus have an important role
in the growth-regulating function of this pathway. Importantly, miR-23b
was predicted to target MDM2 mRNA when assessed separately using
the same algorithm as applied in the miRPath analysis (microT CDS).
We measured MDM2, RCHY1 and CCNG1 in muscle cells derived from
healthy subjects and found an upregulation of MDM2 following
transfection with a miR-23b inhibitor and an upregulation of CCNG1
following transfection with either a miR-23b inhibitor or a miR-27b
inhibitor, while RCHY1 remained unchanged (Figure 3F). These ﬁnd-
ings were concordant with the expression of these genes in muscle
cells derived from T2DM subjects compared to healthy, as both MDM2
and CCNG1 were higher expressed in cells from subjects with T2DM
than in cells from healthy, while no difference was observed in RCHY1
expression (Figure 3G). These data suggest that miR-23b and miR-27b
are promyogenic and are targeting MDM2 and CCNGI in human muscle
stem cells.
3.4. A bi-layered regulation of p53 by miR-23b/27b and its
downstream targets
We next examined the effect of alterations of miR-23b and miR-27b on
p53, the master regulator of growth and cell fate. P53 has an estab-
lished role in myogenesis by inducing the expression of both CDKN1A
(p21) and RB1 (retinoblastoma associated protein, Rb) [41,46]. In-
duction of these proteins are required to exit the cell cycle in order to
continue the myogenic programme [47,48]. p21 and Rb interact with
the myogenic transcription factor, MYOD, to coordinate the early
stages of muscle differentiation [49,50].
We hypothesized that miR-23b and miR-27b would be pro-myogenic by
suppressing the negative regulators of p53, which in turn mediate cell
cycle exit by p53 induction of p21 and Rb and their interaction with
MyoD (Figure 4A). We could not measure any difference in protein
expression of p53 in T2DM muscle cells compared to healthy during
early differentiation (Figure 4B). However, when transfecting T2DM
muscle cells with miR-27b mimics, a modest increase in p53 protein
levels was observed (Figure 4C). Considering that an increase in p53
should be associated with a decrease in MDM2, RCHY1 and Cyclin G1
and an increase in p21, Rb and MyoD, we decided to investigate
whether transfection with miR-23b and miR-27b mimics could rescue
the T2DM muscle cells during early differentiation of muscle.
Indeed, transfection with miR-23b or miR-27b mimics resulted in
robust decrease in at least RCHY1 and CCNG1 at mRNA and protein
levels, while MDM2 was not affected (Figure 4D, E, Figure S4).
Consistently, mimics of both miR-23b and miR-27b mediated
increased mRNA expression of CDKN1A and RB1 as well as p53.
Finally, as a secondary indication of rescue, we assessed the myogenic
markers that were downregulated in T2DM muscle cells, and observed
a substantial upregulation of MYOD during early differentiation
following miR-23b or miR-27b mimics transfection. (Figure 4H). MYOG
and MYH2 were induced during late differentiation following trans-
fection with miR-23b, while PAX7 remained unaltered (Figure 4G and I,
J). Thus, the present data is consistent with the miR-23b/27b cluster
regulating p53 during early stages of muscle differentiation, by tar-
geting its negative regulators, and hereby promoting expression of the
pro-myogenic cell cycle exit genes p21 and Rb, resulting in progres-
sion of the myogenic programme.MOLECULAR METABOLISM 6 (2017) 770e779  2017 The Authors. Published by Elsevier GmbH. This is an op
www.molecularmetabolism.comIn later stages of differentiation, the situation seems to be more
complex. Here, p53 was actually upregulated in T2DM muscle cells
compared to healthy muscle cells, but failed to upregulate Rb and
p21 (Figure S5). In fact, Rb was even downregulated in the T2DM
muscle cells compared to healthy control cells, consistent with the
impaired myogenesis. Possible explanations to this discrepancy
might be the multifaceted function of p53 in cell metabolism and the
extensive control mechanisms regulating the abundance, location,
activity and degradation of p53 [51,52]. Importantly, p53 has been
described to play dual roles in the regulation of myogenesis. It
promotes myogenesis by induced Rb expression [46]. However,
under conditions of stress, p53 induces apoptosis or cellular
senescence and has been shown to directly inhibit myogenin
expression and thus impair late stages of myogenesis [53].
Importantly, we demonstrate in this study that myogenin is down-
regulated during late differentiation in T2DM muscle cells compared
to healthy controls and, additionally is downregulated following
transfection with inhibitors of miR-27b.
4. CONCLUSION
In conclusion, our data constitutes a physiological illustration in human
cells of miRNAs, located at the same locus, acting collectively to
regulate a whole pathway. We present compelling evidence for a novel
miR-23b/27b-p53/Rb pathway, dysregulated in muscle stem cells of
non-obese humans with T2DM, resulting in compromised muscle cell
differentiation in vitro, and possibly contributing to the impaired
muscular phenotype of T2DM in humans.
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